Holen Sie sich die Stockscreener-App
1.35
3.05%
0.04
Schlusskurs vom Vortag:
$1.31
Offen:
$1.32
24-Stunden-Volumen:
144.15K
Relative Volume:
0.06
Marktkapitalisierung:
$55.48M
Einnahmen:
$68.68M
Nettoeinkommen (Verlust:
$-60.84M
KGV:
-0.8438
EPS:
-1.6
Netto-Cashflow:
$-38.42M
1W Leistung:
-9.40%
1M Leistung:
-16.15%
6M Leistung:
-57.01%
1J Leistung:
-78.97%
1-Tages-Spanne:
$1.32
$1.37
1-Wochen-Bereich:
$1.31
$1.48
52-Wochen-Spanne:
$1.31
$9.37
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Vergleichen Sie LUNG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.345 | 54.03M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
126.52 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.94 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.35 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.05 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.00 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Technical signs of recovery in Pulmonx CorporationQuarterly Market Summary & Daily Chart Pattern Signal Reports - newser.com
Is Pulmonx Corporation stock attractive for hedge fundsWeekly Stock Recap & AI Enhanced Market Trend Forecasts - newser.com
Will Pulmonx Corporation stock sustain high P E ratios2025 Major Catalysts & Growth Focused Entry Reports - newser.com
Pulmonx Corporation (LUNG) stock price, news, quote and history - Yahoo Finance UK
Is Pulmonx Corporation stock trading at a premium valuationAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Pulmonx (NASDAQ:LUNG) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Pulmonx Corporation stock entering bullish territoryProfit Target & Stepwise Entry/Exit Trade Alerts - newser.com
Can Pulmonx Corporation stock outperform in 2025 bull marketWeekly Trade Recap & Safe Capital Preservation Plans - newser.com
Tick level data insight on Pulmonx Corporation volatility2025 Valuation Update & Precise Buy Zone Identification - newser.com
Historical volatility pattern of Pulmonx Corporation visualizedTrade Analysis Report & Long-Term Safe Return Strategies - newser.com
Pulmonx Corporation (NASDAQ:LUNG) Q3 2025 Earnings Call Transcript - Insider Monkey
Pulmonx stock rating reiterated at Buy by Stifel after 3Q results - Investing.com Nigeria
LUNG Stock Rating: D. Boral Capital Maintains Buy Rating with $1 - GuruFocus
How Recent Shifts Are Rewriting the Story for Pulmonx - Yahoo Finance
Pulmonx Corp (LUNG) Q3 2025 Earnings Call Highlights: Navigating Growth Challenges and ... By GuruFocus - Investing.com Canada
Pulmonx Corp (LUNG) Q3 2025 Earnings Call Highlights: Navigating Growth Challenges and Strategic Opportunities - GuruFocus
Pulmonx Corp (LUNG) Q3 2025 Earnings Call Highlights: Navigating Growth Challenges and ... - Yahoo Finance
Pulmonx Rides Global Growth On Strong Zephyr Valve Demand - Finimize
Transcript : Pulmonx Corporation, Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
Earnings call transcript: Pulmonx beats Q3 2025 earnings expectations By Investing.com - Investing.com Nigeria
Pulmonx earnings beat by $0.08, revenue topped estimates - Investing.com
Earnings call transcript: Pulmonx beats Q3 2025 earnings expectations - Investing.com
PULMONX Earnings Results: $LUNG Reports Quarterly Earnings - Quiver Quantitative
Pulmonx (LUNG) Exceeds Q3 Revenue Expectations, Aiming for Growt - GuruFocus
Pulmonx (LUNG) Adjusts 2025 Financial Projections - GuruFocus
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Lung treatment firm Pulmonx's Q3 revenue up 5%, net loss narrows marginally - MarketScreener
Pulmonx Reports Third Quarter 2025 Financial Results - The Manila Times
Pulmonx's Earnings: A PreviewPulmonx (NASDAQ:LUNG) - Benzinga
Ready to Jump After Recent Trade: Pulmonx Corp (LUNG) - setenews.com
[Form 3] Pulmonx Corp Initial Statement of Beneficial Ownership - Stock Titan
Using data filters to optimize entry into Pulmonx CorporationJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
A better buy-in window may exist right now for Pulmonx Corp (LUNG) - Setenews
Will Pulmonx Corporation stock maintain momentum in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Visualizing Pulmonx Corporation stock with heatmapsWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
What catalysts could drive Pulmonx Corporation stock higherEarnings Performance Report & Low Volatility Stock Recommendations - newser.com
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulmonx Corp-Aktie (LUNG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Joshi Mehul | Chief Financial Officer & PAO |
Sep 02 '25 |
Sale |
1.60 |
7,936 |
12,698 |
208,489 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Sep 02 '25 |
Sale |
1.60 |
6,543 |
10,469 |
379,788 |
| Lehman David Aaron | GENERAL COUNSEL |
Sep 02 '25 |
Sale |
1.60 |
9,769 |
15,630 |
263,270 |
| Ferrari Richard | Director |
Jun 12 '25 |
Sale |
3.16 |
8,000 |
25,280 |
87,024 |
3.62%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):